The S1P Axis: New Exciting Route for Treating Huntington's Disease

Research output: Contribution to journalReview articlepeer-review


Huntington's disease (HD) is a single-gene inheritable neurodegenerative disorder with an associated complex molecular pathogenic profile that renders it the most ‘curable incurable’ brain disorder. Continuous effort in the field has contributed to the recent discovery of novel potential pathogenic mechanisms. Findings in preclinical models of the disease as well as in human post-mortem brains from affected patients demonstrate that alteration of the sphingosine-1-phosphate (S1P) axis may represent a possible key player in the pathogenesis of the disease and may act as a potential actionable drug target for the development of more targeted and effective therapeutic approaches. The relevance of the path of this new ‘therapeutic route’ is underscored by the fact that some drugs targeting the S1P axis are currently in clinical trials for the treatment of other brain disorders.

Original languageEnglish
Pages (from-to)468-480
Number of pages13
JournalTrends in Pharmacological Sciences
Issue number5
Publication statusPublished - May 1 2018

ASJC Scopus subject areas

  • Toxicology
  • Pharmacology


Dive into the research topics of 'The S1P Axis: New Exciting Route for Treating Huntington's Disease'. Together they form a unique fingerprint.

Cite this